224 related articles for article (PubMed ID: 31942831)
1. Bladder cancer genomics.
Siracusano S; Rizzetto R; Porcaro AB
Urologia; 2020 May; 87(2):49-56. PubMed ID: 31942831
[TBL] [Abstract][Full Text] [Related]
2. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
3. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
4. Genomic Subtyping in Bladder Cancer.
Jalanko T; de Jong JJ; Gibb EA; Seiler R; Black PC
Curr Urol Rep; 2020 Mar; 21(2):9. PubMed ID: 32166460
[TBL] [Abstract][Full Text] [Related]
5. Molecular Subtypes of Bladder Cancer.
McConkey DJ; Choi W
Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
[TBL] [Abstract][Full Text] [Related]
6. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
[TBL] [Abstract][Full Text] [Related]
7. Genetic and molecular markers of urothelial premalignancy and malignancy.
Cordon-Cardo C; Cote RJ; Sauter G
Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
9. The clinical applications of The Cancer Genome Atlas project for bladder cancer.
Creighton CJ
Expert Rev Anticancer Ther; 2018 Oct; 18(10):973-980. PubMed ID: 30081681
[TBL] [Abstract][Full Text] [Related]
10. Genetic subtypes of invasive bladder cancer.
McConkey DJ; Choi W; Dinney CP
Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
[TBL] [Abstract][Full Text] [Related]
11. Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.
Schnitzler T; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Buchner A; Schulz GB; Heidenreich A; Gaisa NT; Knüchel R; Garczyk S
Cell Oncol (Dordr); 2020 Oct; 43(5):807-819. PubMed ID: 32445084
[TBL] [Abstract][Full Text] [Related]
12. Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications.
Minoli M; Kiener M; Thalmann GN; Kruithof-de Julio M; Seiler R
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784716
[TBL] [Abstract][Full Text] [Related]
13. Contemporary Molecular Classification of Urinary Bladder Cancer.
Goutas D; Tzortzis A; Gakiopoulou H; Vlachodimitropoulos D; Giannopoulou I; Lazaris AC
In Vivo; 2021; 35(1):75-80. PubMed ID: 33402452
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
15. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract][Full Text] [Related]
16. Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing?
Loeffler CML; Ortiz Bruechle N; Jung M; Seillier L; Rose M; Laleh NG; Knuechel R; Brinker TJ; Trautwein C; Gaisa NT; Kather JN
Eur Urol Focus; 2022 Mar; 8(2):472-479. PubMed ID: 33895087
[TBL] [Abstract][Full Text] [Related]
17. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
18. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Ascione CM; Napolitano F; Esposito D; Servetto A; Belli S; Santaniello A; Scagliarini S; Crocetto F; Bianco R; Formisano L
Cancer Treat Rev; 2023 Apr; 115():102530. PubMed ID: 36898352
[TBL] [Abstract][Full Text] [Related]
19. New horizons in bladder cancer research.
Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
[TBL] [Abstract][Full Text] [Related]
20. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
